Efficacy Study of Travoprost APS Versus TRAVATAN

Exclusion Criteria

• •Females of childbearing potential not meeting conditions set in the protocol.
• •Severe central visual field loss.
• •Angle Shaffer grade \< 2.
• •Cup/disc ratio \> 0.8 (horizontal or vertical measurement).
• •Best corrected visual acuity (VA) score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal).
• •Intraocular surgery or trauma within last 6 months.
• •Any abnormality preventing reliable applanation tonometry.
• •History of or current ocular pathology (including severe dry eye) that would affect the conduct of the study.
• •Allergy/hypersensitivity to study medications.
• •Unable to discontinue use of all IOP-lowering medications for a minimum wash-out period of 5 to 28 days prior to the Eligibility Visit.
• •Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP.
• •Use of any additional topical or systemic ocular hypotensive medication during the study.
• •Therapy with another investigational agent within 30 days prior to the Screening visit.